CUE insider filings

Cue Biopharma, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-14. Screen CUE transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 5 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Lin Shao-Lee — Chief Executive Officer, Director1—2 legs · 11,087 sh · $305,490—
Ray Sumita — Chief Legal Compliance Officer1—1 leg · 1,844 sh · $51,724—
Meluzio Michael Vincent — VP, Prin. Accounting Officer1—1 leg · 1,144 sh · $32,089—
Garzone Pamela — Director1——1
Sarraf Pasha — Director1——1

Recent insider filings — Cue Biopharma, Inc.

FiledFormInsiderReported transactionsSource
2026-10-144Ray Sumita — Chief Legal Compliance OfficerSale (S): 1,844 @ $28.05EDGAR
2026-10-144Meluzio Michael Vincent — VP, Prin. Accounting OfficerSale (S): 1,144 @ $28.05EDGAR
2026-10-144Lin Shao-Lee — Chief Executive Officer, DirectorSale (S): 10,000 @ $27.50 · Sale (S): 1,087 @ $28.05EDGAR
2026-08-284/AGarzone Pamela — DirectorGrant/award (A): 18,900 @ $0EDGAR
2026-08-284/ASarraf Pasha — DirectorGrant/award (A): 18,400 @ $0EDGAR
2026-08-174Ray Sumita — Chief Legal Compliance OfficerOption exercise (M): 18,196 @ $0 · Sale (S): 2,383 @ $29.37 · Sale (S): 6,442 @ $30.35 · Sale (S): 4 @ $31.13 · Option exercise (M): 18,196 (derivative) @ $0EDGAR
2026-08-174Meluzio Michael Vincent — VP, Prin. Accounting OfficerOption exercise (M): 13,647 @ $0 · Sale (S): 1,519 @ $29.37 · Sale (S): 4,106 @ $30.35 · Sale (S): 3 @ $31.13 · Option exercise (M): 13,647 (derivative) @ $0EDGAR
2026-08-144Lin Shao-Lee — Chief Executive Officer, DirectorOption exercise (M): 109,179 @ $0 · Sale (S): 34,225 @ $26.99 · Sale (S): 5,775 @ $27.75 · Sale (S): 5,423 @ $27.19 · Sale (S): 2,375 @ $28.11 · Sale (S): 10,460 @ $29.48 · +1 moreEDGAR
2026-08-034Ahlers James M — Chief Financial OfficerGrant/award (A): 25,500 @ $0 · Grant/award (A): 51,000 (derivative) @ $0EDGAR
2026-07-304/ALin Shao-Lee — Chief Executive Officer, DirectorGrant/award (A): 90,906 (derivative) @ $11 · Grant/award (A): 45,453 (derivative)EDGAR
2026-07-154Borie Dominique Christian — Chief Medical OfficerGrant/award (A): 31,500 @ $0 · Grant/award (A): 63,000 (derivative) @ $0EDGAR
2026-07-104Meluzio Michael Vincent — VP, Prin. Accounting OfficerGrant/award (A): 40,942 @ $0 · Grant/award (A): 40,942 (derivative) @ $0EDGAR
2026-07-104Meehan Viola Mong — DirectorGrant/award (A): 21,800 @ $0EDGAR
2026-07-104Sarraf Pasha — DirectorGrant/award (A): 21,800 @ $0EDGAR
2026-07-104Garzone Pamela — DirectorGrant/award (A): 21,800 @ $0EDGAR
2026-07-104Camardo Daniel A. — DirectorGrant/award (A): 21,800 @ $0EDGAR
2026-07-104Lin Shao-Lee — Chief Executive Officer, DirectorGrant/award (A): 327,537 @ $0 · Grant/award (A): 327,537 (derivative) @ $0EDGAR
2026-07-104Ray Sumita — Chief Legal Compliance OfficerGrant/award (A): 54,589 @ $0 · Grant/award (A): 54,589 (derivative) @ $0EDGAR
2026-06-084Camardo Daniel A. — DirectorGrant/award (A): 1,626 (derivative) @ $0EDGAR
2026-06-034Lin Shao-Lee — Chief Executive Officer, DirectorPurchase (P): 90,906 (derivative) @ $11 · Purchase (P): 45,453 (derivative)EDGAR
2026-06-024Meehan Viola Mong — DirectorGrant/award (A): 1,626 (derivative) @ $0EDGAR
2026-05-074Lin Shao-Lee — CHIEF EXECUTIVE OFFICER, DirectorGrant/award (A): 327,537 @ $0 · Grant/award (A): 655,074 (derivative) @ $0EDGAR
2026-04-104Sandercock Colin — SVP, GENERAL COUNSELGrant/award (A): 200,000 (derivative) @ $0EDGAR
2026-04-104Warren Lucinda — CHIEF BUSINESS OFFICERGrant/award (A): 250,000 (derivative) @ $0EDGAR
2026-04-104Baker Daniel G. — CHIEF DEVELOPMENT OFFICERGrant/award (A): 100,000 (derivative) @ $0EDGAR
2026-01-064Morich Frank — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2026-01-064Garzone Pamela — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2026-01-064Verheyen Patrick — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2026-01-064Sarraf Pasha — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2026-01-064Kiener Peter A — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2026-01-064Broadfoot Jill Marie — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2026-01-024Sarraf Pasha — DirectorPurchase (P): 4,229 @ $0.31 · Purchase (P): 77,148 @ $0.30 · Purchase (P): 86,947 @ $0.32 · Purchase (P): 78,116 @ $0.31 · Purchase (P): 77,417 @ $0.30EDGAR
2025-12-054Sandercock Colin — SVP, GENERAL COUNSELGrant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0EDGAR
2025-11-254Warren Lucinda — CHIEF BUSINESS OFFICERGrant/award (A): 125,000 (derivative) @ $0EDGAR
2025-11-254Baker Daniel G. — CHIEF DEVELOPMENT OFFICERGrant/award (A): 50,000 (derivative) @ $0EDGAR
2025-10-024Azam Usman — CHIEF EXECUTIVE OFFICER, DirectorGrant/award (A): 1,875,000 (derivative) @ $0EDGAR
2025-06-064Broadfoot Jill Marie — DirectorGrant/award (A): 48,800 (derivative) @ $0EDGAR
2025-03-254Millar Kerri-Ann — CHIEF FINANCIAL OFFICERGrant/award (A): 200,000 (derivative) @ $0EDGAR
2025-03-254Baker Daniel G. — CHIEF DEVELOPMENT OFFICERGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-03-254Sandercock Colin — SVP, GENERAL COUNSELGrant/award (A): 200,000 (derivative) @ $0EDGAR
2025-03-254Warren Lucinda — CHIEF BUSINESS OFFICERGrant/award (A): 250,000 (derivative) @ $0EDGAR
2025-03-254Levisetti Matteo — Chief Medical OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2025-03-254PASSERI DANIEL R — CHIEF EXECUTIVE OFFICER, DirectorGrant/award (A): 450,000 (derivative) @ $0EDGAR
2025-03-124Sarraf Pasha — DirectorGrant/award (A): 48,800 (derivative) @ $0EDGAR
2025-01-034Morich Frank — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2025-01-034Verheyen Patrick — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2025-01-034Garzone Pamela — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2025-01-034Kiener Peter A — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2025-01-034DRISCOLL FREDERICK W — DirectorGrant/award (A): 24,400 (derivative) @ $0EDGAR
2024-12-184PASSERI DANIEL R — CHIEF EXECUTIVE OFFICER, DirectorPurchase (P): 30,000 @ $1.03EDGAR

Recent 8-K events — Cue Biopharma, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-168-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-218-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-148-K2.02 — Results of Operations and Financial ConditionEDGAR
2026-08-038-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-07-108-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-038-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-028-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
EDGAR
2026-05-148-K9.01 — Financial Statements and ExhibitsEDGAR
2026-05-018-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-228-K3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=CUE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs